ArticleInternational journal of nephrology2026
Serological Profile of Hepatitis B, C, and D and Factors Associated With Hepatitis B Exposure and Vaccination Among Hemodialysis Patients in Northeastern Brazil.
Article in International journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Serological Profile of Hepatitis B, C, and D and Factors Associated With Hepatitis B Exposure and Vaccination Among Hemodialysis Patients in Northeastern Brazil.International journal of nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hemodialysis patients are at increased risk for viral hepatitis due to treatment-related exposures and transmission routes, potentially worsening liver and kidney disease. However, updated regional data in Brazil are scarce. This study evaluated the seroprevalence of hepatitis B, C, and D viruses (HBV, HCV, and HDV) and analyzed risk factors associated with HBV infection among patients undergoing hemodialysis in Northeast Brazil. Methods: This study corresponds to a cross-sectional evaluation of 293 patients from two hemodialysis clinics. Serological markers (HBsAg, anti-HDV, anti-HBc, anti-HBs, and anti-HCV) were analyzed by chemiluminescence, and the quantification of viral load was measured by real-time PCR. Sociodemographic and risk-related characteristics were collected via questionnaire. Statistical analyses included chi-square and Fisher tests ( Results: The prevalence of hepatitis B (HBsAg+) and hepatitis C (anti-HCV+) was 2.4% and 4.1%, respectively. Regarding hepatitis B serological status, 17.2% presented markers of exposure (HBsAg and/or anti-HBc+), 35.6% were susceptible, and 47.1% had probable vaccine-induced immunity (isolated anti-HBs+). Male sex was associated with HBV exposure, whereas female sex was associated with susceptibility ( Conclusion: HBV and HCV prevalence was higher than the national average in hemodialysis, with gender disparities between exposed and susceptible and low vaccination coverage, especially in drug users. Although no anti-HDV reactivity was found, investigating hepatitis D in this population remains relevant to improving understanding of its geographical distribution and clinical impact. It is recommended to reinforce screening, vaccination, and safety protocols in hemodialysis clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.